Growth Hormone Therapy Effective at Increasing Anemics' Height During Childhood

Article

For children with Diamond-Blackfan Anemia (DBA) - an inherited condition defined by low red blood cell counts and limited progenitor cells in the bone marrow - growth hormone (GH) therapy was found to increase the short stature of patients - a symptom not widely analyzed.

For children with Diamond-Blackfan Anemia (DBA) — an inherited condition defined by low red blood cell counts and limited progenitor cells in the bone marrow — growth hormone (GH) therapy was found to increase the short stature of patients — a symptom not widely analyzed.

Commonly born smaller than average, GBA patients often experienced cellular mutations that often go undiscovered. Also experiencing iron overload, previous research has implicated this factor in GBA (and other chronic anemia) patients’ decreased growth rates despite secreting adequate amounts of GHs.

For their study, Jonathan C. Howell, MD, PhD, and his colleagues analyzed the annual growth velocity (GV) and height-for-age Z-scores (HAZ) of 44 DBA patients aged 2-20 years-old who did not undergo GH therapy. Investigators compared the height information with 19 DBA patients receiving hormones (mean dose 0.3 mg/kg/week, range 0.2 to 0.4 mg/kg/week).

While investigators documented that the GH patients were shorter than subjects not treated before their regimen began, they experienced a significant increase in their rate of growth within the first 2 years of their therapy. For every 4 years of treatment, the researchers noted that GH participants’ HAZ scores were better than baseline standards.

“Additionally, after 2 years of GH treatment, HAZ scores were not significantly different from the control DBA population, indicating successful catch-up growth relative to peers with DBA,” the authors also reported in Pediatric Blood Cancer.

In light of their discovery, the investigators pressed for the use of personalized growth charts for DBA patients to identify which patients would make good GH therapy candidates.

“Based both on the frequent occurrence of short stature in children with DBA, and on data presented here, we recommend careful consideration of GH therapy at a young age for those patients with DBA who have significant short stature to improve GV and overall HAZ scores,” the writers also recommended.

Recent Videos
Ben Samelson-Jones, MD, PhD, assistant professor pediatric hematology, Perelman School of Medicine, University of Pennsylvania and Associate Director, Clinical In Vivo Gene Therapy, Children’s Hospital of Philadelphia
Manali Kamdar, MD, the associate professor of medicine–hematology and clinical director of lymphoma services at the University of Colorado
Steven W. Pipe, MD, a professor of pediatric hematology/oncology at CS Mott Children’s Hospital
Haydar Frangoul, MD, the medical director of pediatric hematology/oncology at Sarah Cannon Research Institute and Pediatric Transplant and Cellular Therapy Program at TriStar Centennial
David Barrett, JD, the chief executive officer of ASGCT
Georg Schett, MD, vice president research and chair of internal medicine at the University of Erlangen – Nuremberg
David Barrett, JD, the chief executive officer of ASGCT
Bhagirathbhai R. Dholaria, MD, an associate professor of medicine in malignant hematology & stem cell transplantation at Vanderbilt University Medical Center
Caroline Diorio, MD, FRCPC, FAAP, an attending physician at the Cancer Center at Children's Hospital of Philadelphia
Related Content
© 2024 MJH Life Sciences

All rights reserved.